Literature DB >> 9643320

Wegener's granulomatosis: disease course, assessment of activity and extent and treatment.

K de Groot1, W L Gross.   

Abstract

Wegener's granulomatosis (WG) belongs to the group of necrotizing primary systemic vasculitides of unknown etiology, that are associated with anti-neutrophil cytoplasmic antibodies. The pathological hallmark of WG is the coexistence of vasculitis and granuloma. Due to more sensitive diagnostic instruments, especially ANCA testing, the incidence of diagnosis of WG has risen in the past ten years. Although the precise pathophysiology is not understood yet, there is ample evidence that ANCA, which can lead to cytotoxic reactions in the vascular texture, play a major role, possibly promoted by a dysbalance in the anti-idiotypic network. The clinical disease course is typically two-phasic, beginning with a granulomatous inflammation of the upper respiratory tract, that usually is followed by a generalized vasculitic phase, that can range from mild organ dysfuntion to life threatening multi-organ failure. Consequently, diagnostic procedures, patients' assessment and therapeutic regimens need to be individualized, adapted to stage and activity of the disease as well as standardized.

Entities:  

Mesh:

Year:  1998        PMID: 9643320     DOI: 10.1191/096120398678920118

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; F Moosig; A Gause; K Herlyn; E Csernok; H Hansen; W L Gross
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 2.  The role of the T cell in autoimmune inflammation.

Authors:  Alla Skapenko; Jan Leipe; Peter E Lipsky; Hendrik Schulze-Koops
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

3.  Unexpectedly difficult intubation caused by subglottic stenosis in Wegener's granulomatosis.

Authors:  Hiroki Daijo; Satoshi Takabuchi; Toyohiko Ohigashi; Yukiko Yoshikawa; Tetsutaro Shinomura
Journal:  J Anesth       Date:  2010-01-23       Impact factor: 2.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.